Inhibition of the autocrine IL6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+breast cancers

被引：0
|
作者：
Silva, J.
Rodriguez-Barrueco, R.
Yu, J.
Kalinsky, K.
Maurer, M.
Califano, A.
机构：
[1] Mt Sinai Sch Med, New York, NY USA
[2] Columbia Univ, Nyc, NY USA
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-PD3-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD3-03
引用
收藏
页数：2
相关论文
共 50 条
  • [31] LY2784544, a small molecule JAK2 inhibitor, induces apoptosis in inflammatory breast cancer spheres through targeting IL-6-JAK-STAT3 pathway
    Ma, Liandong
    Zhao, Baohui
    Walgren, Richard A.
    Clayton, Joshua R.
    Burkholder, Timothy R.
    CANCER RESEARCH, 2011, 71
  • [32] Ginsenoside Rh2 regulates triple-negative breast cancer proliferation and apoptosis via the IL-6/JAK2/STAT3 pathway
    Ding, Rumeng
    Kan, Quancheng
    Wang, Ting
    Xiao, Ran
    Song, Yanan
    Li, Duolu
    FRONTIERS IN PHARMACOLOGY, 2025, 15
  • [33] Postmenopausal obese mammary adipocytes promote breast tumorigenesis via the LCN2/IL6/STAT3 signaling axis
    Roy, Roopali
    Man, Emily
    Gonzalez, Katherine
    Merritt, Lauren
    Daisy, Cassandra
    Aldakhallah, Rama
    Sun, Liang
    Isaac, Biju
    Rockowitz, Shira
    Lotz-Bousvaros, Margaret
    Pories, Susan
    Moses, Marsha A.
    CANCER RESEARCH, 2022, 82 (12)
  • [34] STAT4 facilitates PD-L1 level via IL-12R/JAK2/STAT3 axis and predicts immunotherapy response in breast cancer
    Zhou, Jianbo
    Wan, Feng
    Wang, Li
    Peng, Cheng
    Huang, Ruizhen
    Peng, Fu
    MEDCOMM, 2023, 4 (06):
  • [35] tGLI1 and IL-6/IL-6R/GP130/STAT3 pathways cooperate to promote breast cancer stem cells and are co-activated in HER2-enriched and triple-negative breast cancers
    Manore, Sara G.
    Doheny, Daniel L.
    Zhu, Dongqin
    Wong, Grace L.
    Regua, Angelina T.
    Arrigo, Austin
    Wagner, Calvin J.
    Najjar, Mariana
    Lo, Hui-Wen
    CANCER RESEARCH, 2022, 82 (12)
  • [36] Glioblastoma-induced inhibition of Langerhans cell differentiation from CD34+ precursors is mediated by IL-6 but unaffected by JAK2/STAT3 inhibition
    van Cruijsen, Hester
    Oosterhoff, Dinja
    Lindenberg, Jelle J.
    Lougheed, Sinead M.
    Fehres, Cynthia
    Weijers, Karin
    van Boerdonk, Robert
    Giaccone, Giuseppe
    Scheper, Rik J.
    Hoekman, Klaas
    de Gruijl, Tanja D.
    IMMUNOTHERAPY, 2011, 3 (09) : 1051 - 1061
  • [37] Induction of metastatic potential by TrkB via activation of IL6/JAK2/STAT3 and PI3K/AKT signaling in breast cancer
    Kim, Min Soo
    Lee, Won Sung
    Jeong, Joon
    Kim, Seong-Jin
    Jin, Wook
    ONCOTARGET, 2015, 6 (37) : 40158 - 40171
  • [38] Evaluating the role of CDK4/6 inhibition on STAT3 activation in a transgenic mouse model of HER2-positive breast cancer
    Adesoye, Taiwo
    Luo, Linjie
    Bui, Tuyen
    Kim, Serena
    Wingate, Hannah
    Tripathy, Debu
    Hunt, Kelly
    Keyomarsi, Khandan
    CANCER RESEARCH, 2024, 84 (09)
  • [39] A phosphoglycerate mutase 1 allosteric inhibitor overcomes drug resistance to EGFR-targeted therapy via disrupting IL-6/JAK2/STAT3 signaling pathway in lung adenocarcinoma
    Liang, Qian
    Gong, Miaomiao
    Zou, Jing-Hua
    Luo, Ming-yu
    Jiang, Lu-lu
    Wang, Cheng
    Shen, Ning-xiang
    Zhang, Mo-cong
    Xu, Lu
    Lei, Hui-min
    Zhang, Ke-Ren
    Zhang, Rui
    Zhuang, Guanglei
    Zhu, Liang
    Chen, Hong-zhuan
    Zhou, Lu
    Shen, Ying
    DRUG RESISTANCE UPDATES, 2023, 68
  • [40] Effect of Inhibition of the JAK2/STAT3 Signaling Pathway on the Th17/IL-17 Axis in Acute Cellular Rejection After Heart Transplantation in Mice
    Zhang, Ming
    Xu, Ming
    Wang, Kaijie
    Li, Long
    Zhao, Jinping
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2021, 77 (05) : 614 - 620
12345